Infection, recovery and re-infection of farmed mink with SARS-CoV-2.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
11 2021
Historique:
received: 11 08 2021
accepted: 27 10 2021
revised: 29 11 2021
pubmed: 16 11 2021
medline: 15 12 2021
entrez: 15 11 2021
Statut: epublish

Résumé

Mink, on a farm with about 15,000 animals, became infected with SARS-CoV-2. Over 75% of tested animals were positive for SARS-CoV-2 RNA in throat swabs and 100% of tested animals were seropositive. The virus responsible had a deletion of nucleotides encoding residues H69 and V70 within the spike protein gene as well as the A22920T mutation, resulting in the Y453F substitution within this protein, seen previously in mink. The infected mink recovered and after free-testing of 300 mink (a level giving 93% confidence of detecting a 1% prevalence), the animals remained seropositive. During further follow-up studies, after a period of more than 2 months without any virus detection, over 75% of tested animals again scored positive for SARS-CoV-2 RNA. Whole genome sequencing showed that the viruses circulating during this re-infection were most closely related to those identified in the first outbreak on this farm but additional sequence changes had occurred. Animals had much higher levels of anti-SARS-CoV-2 antibodies in serum samples after the second round of infection than at free-testing or during recovery from initial infection, consistent with a boosted immune response. Thus, it was concluded that following recovery from an initial infection, seropositive mink were readily re-infected by SARS-CoV-2.

Identifiants

pubmed: 34780574
doi: 10.1371/journal.ppat.1010068
pii: PPATHOGENS-D-21-01633
pmc: PMC8629378
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
RNA, Viral 0
Spike Glycoprotein, Coronavirus 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010068

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist

Références

Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
Lancet Infect Dis. 2020 Sep;20(9):1051-1060
pubmed: 32539986
NPJ Vaccines. 2021 May 10;6(1):67
pubmed: 33972565
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Lancet Microbe. 2020 Sep;1(5):e218-e225
pubmed: 32838346
Euro Surveill. 2021 Feb;26(5):
pubmed: 33541485
mSphere. 2020 Jun 24;5(3):
pubmed: 32581081
Nat Commun. 2020 Nov 25;11(1):5986
pubmed: 33239633
Science. 2020 May 29;368(6494):1016-1020
pubmed: 32269068
Sci Immunol. 2020 Dec 22;5(54):
pubmed: 33443036
Occup Environ Med. 2021 Dec;78(12):893-899
pubmed: 34330815
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478625
Euro Surveill. 2020 Jun;25(23):
pubmed: 32553059
Animals (Basel). 2021 Jan 12;11(1):
pubmed: 33445704
Cell Rep. 2021 Jun 29;35(13):109292
pubmed: 34166617
Emerg Infect Dis. 2021 Feb;27(2):547-551
pubmed: 33207152
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
Front Microbiol. 2021 Jun 25;12:698944
pubmed: 34248922
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Natl Sci Rev. 2020 Dec 08;8(3):nwaa291
pubmed: 34676095
Sci Adv. 2020 Jun 17;6(25):eabb5813
pubmed: 32596474
J Infect. 2021 Mar;82(3):399-406
pubmed: 33589297
Emerg Infect Dis. 2021 Mar;27(3):928-931
pubmed: 33350923

Auteurs

Thomas Bruun Rasmussen (TB)

Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen S, Denmark.

Jannik Fonager (J)

Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen S, Denmark.

Charlotte Sværke Jørgensen (CS)

Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen S, Denmark.

Ria Lassaunière (R)

Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen S, Denmark.

Anne Sofie Hammer (AS)

Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg C, Denmark.

Michelle Lauge Quaade (ML)

Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg C, Denmark.

Anette Boklund (A)

Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg C, Denmark.

Louise Lohse (L)

Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen S, Denmark.

Bertel Strandbygaard (B)

Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen S, Denmark.

Morten Rasmussen (M)

Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen S, Denmark.

Thomas Yssing Michaelsen (TY)

Department of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.

Sten Mortensen (S)

Danish Veterinary and Food Administration, Glostrup, Denmark.

Anders Fomsgaard (A)

Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen S, Denmark.

Graham J Belsham (GJ)

Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg C, Denmark.

Anette Bøtner (A)

Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg C, Denmark.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH